Safety, Tolerability, and Efficacy of Etrasimod (APD334) in Patients With Primary Biliary Cholangitis



Status:Recruiting
Conditions:Gastrointestinal
Therapuetic Areas:Gastroenterology
Healthy:No
Age Range:18 - 80
Updated:11/17/2018
Start Date:December 15, 2017
End Date:December 2019
Contact:Cassandra Schroeder
Email:cschroeder@arenapharm.com
Phone:+1 858 529 2489

Use our guide to learn which trials are right for you!

An Open-label, Pilot, Proof of Concept Study to Evaluate the Safety, Tolerability, and Efficacy of Oral Etrasimod (APD334) in Patients With Primary Biliary Cholangitis

The purpose of this open-label, pilot, proof of concept study is to evaluate the safety,
tolerability, and efficacy of oral etrasimod (APD334) in patients with primary biliary
cholangitis (PBC).


Key Inclusion Criteria:

- Males or females aged 18 to 80 years (inclusive) at the time of screening, with
confirmed PBC diagnosis based upon at least 2 of 3 criteria:

- AMA titer >1:40 on immunofluorescence or M2 positive by enzyme-linked
immunosorbent assay (ELISA) or positive PBC-specific antinuclear antibodies
(anti-GP210 and/or anti-SP100)

- ALP >1.5 x ULN for at least 6 months

- Liver biopsy findings consistent with PBC

- Use of UDCA for at least 6 months prior to screening (stable dose for at least 3
months immediately prior to screening)

- Patients must have ALP >1.5 x ULN but <10 x ULN, ALT and AST <5 x ULN, and total
bilirubin
- AST, ALT, ALP, and total bilirubin must have 2 values at least 4 weeks apart that are
within 20% of each other

Key Exclusion Criteria:

- Chronic liver disease of a non-PBC etiology. However, PBC patients accompanied with
primary Sjögren's syndrome (pSS) are eligible to be enrolled.

- History or evidence of clinically significant hepatic decompensation

- Medical conditions that may cause non-hepatic increases in ALP (e.g., Paget's disease)

- Clinically significant infections within 6 weeks prior to treatment start, or
infection with hepatitis C virus anytime in the past

- Immunosuppressive, immunomodulating, or investigational agents within 30 days prior to
treatment start

- Treatment with OCA within 30 days prior to Day 1

Note: Other protocol defined Inclusion/Exclusion criteria may apply
We found this trial at
5
sites
San Antonio, Texas 78215
Principal Investigator: Eric Lawitz, MD
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
1200 Moursund Street
Houston, Texas 77030
(713) 798-4951
Principal Investigator: John Vierling, MD
Baylor College of Medicine Baylor College of Medicine in Houston, the only private medical school...
?
mi
from
Houston, TX
Click here to add this to my saved trials
Camperdown, New South Wales 2050
?
mi
from
Camperdown,
Click here to add this to my saved trials
Sacramento, California 95817
Principal Investigator: Chris Bowlus, MD
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
5300 Tallman Ave NW
Seattle, Washington 98122
(206) 782-2700
Principal Investigator: Kris Kowdley, MD
Swedish Medical Center Since 1910, Swedish has been the region's hallmark for excellence in health...
?
mi
from
Seattle, WA
Click here to add this to my saved trials